♥

Bal Pharma Limited

ISIN : INE083D01012
NSE : BALPHARMA
BSE : 524824
Face Value : 10
Industry : Pharmaceuticals & Drugs

EPS : 4.96
EPS (TTM) : 5.06
Price to Earning (P/E) : 16.92
Book Value : 43.84
Price to Bookvalue (P/B) : 1.91
Dividend Yield : 1 %
Return on Equity (ROE) : 11.19 %
Return on Capital Employed (ROCE) : 12.13 %

Bal Pharma share price (02-Apr-2026)
National Stock Exchange NSE
Open / Close	0 - 0 NAN %
Low / High	0 - 0 NAN %
Trade Volume	0
52 Week Low / High	0 - 0 NAN %
Bombay Stock Exchange BSE
Open / Close	63 - 64.01 1.6 %
Low / High	62.27 - 65.2 4.7 %
Trade Volume	432
52 Week Low / High	59.69 - 112.97 89.3 %

YOU MAY ALSO LIKE

CAGR Calculator
Check your investment returns using our CAGR / Investment Growth Calculator
Share Market basics for beginners
Share Market jargons in simple terms
Low PE ratio stocks
Undervalued, low PE ratio stocks on Stock exchange NSE and BSE
How much money do you need to retire
Know how much money do you need to retire, before how much to invest ?
High dividend stocks
High dividend yield stocks on Stock exchange NSE and BSE
Stock market course tutorial
Stock Market Investment Course explained in simple words.

Consolidated Standalone

CONSOLIDATED QUARTERLY RESULT FOR BAL PHARMA LIMITED

Date End	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	740.49	698.39	753.07	766.19	824.51	703.87	925.43	816.64	946.26	743.59
Total Income	777.53	700.83	753.55	770.79	826.39	705.44	926.85	817.59	970.8	751.77
Total Expenditure	706.03	648.06	695.33	704.67	742.87	639.43	848.45	738.69	850.34	678.94
Other Income	37.04	2.44	0.48	4.6	1.88	1.57	1.42	0.95	24.54	8.18
Operating Profit	71.5	52.77	58.22	66.12	83.52	66.01	78.4	78.9	120.46	72.83
Interest	24.51	23.68	28.55	31.1	38.53	36.36	38.21	36.61	41.4	42.38
PBDT	46.99	29.09	29.67	35.02	44.99	29.65	40.19	42.29	79.06	30.45
Depreciation	24.21	22.26	23.68	24.48	20.87	25.34	24.19	29.63	21.55	24.28
Profit Before Tax	22.78	6.83	5.99	10.54	24.12	4.31	16	12.66	57.51	6.17
Tax	0.9	3.99	4.73	4.63	7.94	3.36	6.3	4.17	2.19	3.58
Profit After Tax	21.88	2.84	1.26	5.91	16.18	0.95	9.7	8.49	55.32	2.59
Net Profit	21.88	2.84	1.26	5.91	16.18	0.95	9.7	8.49	55.32	2.59
Equity Capital	148.22	148.22	155.72	156.9	156.9	156.9	156.9	158.04	158.04	158.04
Face Value (IN RS)	10	10	10	10	10	10	10	10	10	10
Reserves									534.9
Calculated EPS	1.33	0.19	0.07	0.37	1.02	0.05	0.6	0.56	3.46	0.16
Diluted Eps After Extraordinary Items	1.3	0.19	0.07	0.38	1.04	0.06	0.62	0.54	3.74	0.16
Diluted Eps Before Extraordinary Items	1.3	0.19	0.07	0.38	1.04	0.06	0.62	0.54	3.74	0.16

STANDALONE QUARTERLY RESULT FOR BAL PHARMA LIMITED

Date End	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	737.59	695.09	750.55	765.63	819.72	701.66	922.99	814.95	945.8	731.27
Total Income	777.03	700.71	754.36	773.35	824.11	706.13	927.13	817.52	968.14	739.42
Total Expenditure	702.76	640.66	690.4	702.59	737.02	633.25	846.44	738.66	842.63	660.56
Other Income	39.44	5.62	3.82	7.72	4.39	4.47	4.13	2.57	22.34	8.15
Operating Profit	74.27	60.05	63.96	70.76	87.09	72.88	80.69	78.86	125.51	78.86
Interest	24.48	23.68	28.32	31.18	38.37	36.36	38.21	36.61	41.18	37.05
PBDT	49.79	36.37	35.64	39.58	48.72	36.52	42.48	42.25	84.33	41.81
Depreciation	21.13	18.3	19.62	20.26	16.63	21.22	20.15	25.51	17.63	20.76
Profit Before Tax	28.66	18.07	16.02	19.32	32.09	15.3	22.33	16.74	66.7	21.05
Tax	0.9	3.99	4.73	4.62	10.88	3.36	6.3	4.17	4.51	3.58
Profit After Tax	27.76	14.08	11.29	14.7	21.21	11.94	16.03	12.57	62.19	17.47
Net Profit	27.76	14.08	11.29	14.7	21.21	11.94	16.03	12.57	62.19	17.47
Equity Capital	148.22	148.22	155.72	156.9	156.89	156.9	156.9	158.04	158.04	158.04
Face Value (IN RS)	10	10	10	10	10	10	10	10	10	10
Reserves									897.77
Calculated EPS	1.87	0.95	0.73	0.94	1.35	0.76	1.02	0.8	3.94	1.11
Diluted Eps After Extraordinary Items	1.83	0.93	0.73	0.95	1.36	0.76	1.02	0.8	4.18	1.11
Diluted Eps Before Extraordinary Items	1.83	0.93	0.73	0.95	1.36	0.76	1.02	0.8	4.18	1.11

Consolidated Standalone

CONSOLIDATED ANNUAL RESULT FOR BAL PHARMA LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	2812.15	3042.16	3392.2
Total Income	2863.66	3051.57	3420.68
Total Expenditure	2577.4	2790.94	3076.92
Other Income	51.52	9.41	28.48
Operating Profit	286.26	260.63	343.76
Interest	104.05	121.86	152.58
PBDT	182.21	138.77	191.18
Depreciation	90.4	91.28	100.71
Profit Before Tax	91.81	47.49	90.47
Tax	34.77	21.29	16.02
Profit After Tax	57.04	26.2	74.45
Net Profit	57.04	26.2	74.45
Equity Capital	148.22	156.9	158.04
Face Value (IN RS)	10	10	10
Reserves	438.04	480.99	534.9
Calculated EPS	3.79	1.64	4.68
Diluted Eps After Extraordinary Items	3.71	1.68	4.96
Diluted Eps Before Extraordinary Items	3.71	1.68	4.96

STANDALONE ANNUAL RESULT FOR BAL PHARMA LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	2803.65	3030.99	3385.4
Total Income	2868.56	3052.54	3418.92
Total Expenditure	2571.64	2770.67	3060.99
Other Income	64.9	21.55	33.52
Operating Profit	296.92	281.87	357.93
Interest	103.99	121.56	152.35
PBDT	192.93	160.31	205.58
Depreciation	72.37	74.81	84.52
Profit Before Tax	120.56	85.5	121.06
Tax	34.77	24.23	18.34
Profit After Tax	85.79	61.27	102.72
Net Profit	85.79	61.27	102.72
Equity Capital	148.22	156.9	158.04
Face Value (IN RS)	10	10	10
Reserves			897.77
Calculated EPS	5.79	3.91	6.5
Diluted Eps After Extraordinary Items	5.67	3.94	6.75
Diluted Eps Before Extraordinary Items	5.67	3.94	6.75

Consolidated Standalone

CONSOLIDATED PROFIT / LOSS FOR BAL PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	250.53 Cr	281.21 Cr	304.22 Cr	339.22 Cr
Sales	246.94 Cr	279.7 Cr	301.59 Cr	326.34 Cr
Processing Charges / Service Income	0	21,000	11.52 Lk	84,000
Net Sales	250.53 Cr	281.21 Cr	304.22 Cr	339.22 Cr
Increase/Decrease in Stock	5.05 Cr	-4.89 Cr	-17.87 Cr	-1.06 Cr
Raw Material Consumed	135.82 Cr	160.63 Cr	176.82 Cr	176.86 Cr
Opening Raw Materials	24.96 Cr	22.72 Cr	31.1 Cr	36.35 Cr
Purchases Raw Materials	123.14 Cr	160.58 Cr	170.61 Cr	154.22 Cr
Closing Raw Materials	22.71 Cr	31.1 Cr	36.35 Cr	24.95 Cr
Other Direct Purchases / Brought in cost	10.43 Cr	8.43 Cr	11.45 Cr	11.24 Cr
Power & Fuel Cost	4.98 Cr	5.89 Cr	7.73 Cr	8.73 Cr
Electricity & Power	4.98 Cr	3.69 Cr	4.52 Cr	5.36 Cr
Oil, Fuel & Natural gas	0	1.92 Cr	3 Cr	3.08 Cr
Employee Cost	41.88 Cr	47.25 Cr	55.3 Cr	60.38 Cr
Salaries, Wages & Bonus	36.92 Cr	41.89 Cr	49.27 Cr	53.94 Cr
Contributions to EPF & Pension Funds	1.74 Cr	1.61 Cr	1.9 Cr	2.37 Cr
Workmen and Staff Welfare Expenses	2.22 Cr	2.65 Cr	3.04 Cr	2.86 Cr
Other Manufacturing Expenses	18.61 Cr	21.92 Cr	27.76 Cr	29.09 Cr
Sub-contracted / Out sourced services	3.28 Cr	3.05 Cr	4.93 Cr	4.41 Cr
Repairs and Maintenance	3.2 Cr	4.64 Cr	5.41 Cr	5.63 Cr
Packing Material Consumed	10.08 Cr	11.79 Cr	13.83 Cr	15.96 Cr
General and Administration Expenses	5.45 Cr	8.07 Cr	10.16 Cr	11.96 Cr
Rent , Rates & Taxes	1.49 Cr	2.08 Cr	2.97 Cr	3.24 Cr
Insurance	46.18 Lk	53.12 Lk	74.14 Lk	1.46 Cr
Printing and stationery	37.79 Lk	32.12 Lk	43.79 Lk	45.31 Lk
Professional and legal fees	1.44 Cr	2.6 Cr	2.3 Cr	2.3 Cr
Traveling and conveyance	61.45 Lk	67.73 Lk	2.02 Cr	2.82 Cr
Selling and Distribution Expenses	10.27 Cr	14.86 Cr	16.36 Cr	18.99 Cr
Advertisement & Sales Promotion	1.57 Cr	2.25 Cr	3.08 Cr	3.3 Cr
Sales Commissions & Incentives	2.58 Cr	2.64 Cr	3.83 Cr	8.79 Cr
Freight and Forwarding	6.12 Cr	9.93 Cr	9.37 Cr	6.8 Cr
Miscellaneous Expenses	3.84 Cr	3.51 Cr	2.72 Cr	2.57 Cr
Provision for doubtful debts	31.75 Lk	15.88 Lk	18.2 Lk	19.3 Lk
Loss on disposal of fixed assets(net)	55,000	0	0	0
Loss on foreign exchange fluctuations	1.86 Cr	12,000	1.42 Cr	91.05 Lk
Total Expenditure	225.88 Cr	257.24 Cr	278.97 Cr	307.51 Cr
Other Income	1.14 Cr	5.15 Cr	94.06 Lk	2.85 Cr
Interest Received	31.42 Lk	37.01 Lk	23.13 Lk	55.96 Lk
Profit on sale of Fixed Assets	2.1 Lk	1.23 Cr	3.94 Lk	8.27 Lk
Provision Written Back	58.27 Lk	1.76 Cr	0	62.04 Lk
Foreign Exchange Gains	0	68.59 Lk	0	0
Operating Profit	25.78 Cr	29.13 Cr	26.19 Cr	34.56 Cr
Interest	12.16 Cr	10.91 Cr	12.31 Cr	15.44 Cr
Interest on Term Loan	3.26 Cr	2.77 Cr	3.7 Cr	3.12 Cr
Bank Charges etc	1.62 Cr	2.03 Cr	1.82 Cr	2.54 Cr
PBDT	13.62 Cr	18.22 Cr	13.88 Cr	19.12 Cr
Depreciation	9.52 Cr	9.04 Cr	9.13 Cr	10.07 Cr
Profit Before Taxation & Exceptional Items	4.1 Cr	9.18 Cr	4.75 Cr	9.05 Cr
Profit Before Tax	4.1 Cr	9.18 Cr	4.75 Cr	9.05 Cr
Provision for Tax	-60.95 Lk	3.48 Cr	2.13 Cr	1.6 Cr
Current Income Tax	37.87 Lk	4.48 Cr	2.58 Cr	3.2 Cr
Deferred Tax	-98.82 Lk	-1.94 Cr	9.81 Lk	84.63 Lk
Profit After Tax	4.71 Cr	5.7 Cr	2.62 Cr	7.45 Cr
Minority Interest	3.02 Lk	-9.34 Lk	-4.75 Lk	-5.35 Lk
Consolidated Net Profit	4.74 Cr	5.61 Cr	2.57 Cr	7.39 Cr
Profit Balance B/F	12.59 Cr	9.45 Cr	13.58 Cr	14.6 Cr
Appropriations	17.33 Cr	15.06 Cr	16.15 Cr	21.99 Cr
Other Appropriation	7.88 Cr	1.48 Cr	1.56 Cr	2.74 Cr
Equity Dividend %	10	0	10	12
Earnings Per Share	3.2	3.79	1.64	4.68
Adjusted EPS	3.2	3.79	1.64	4.68

STANDALONE PROFIT / LOSS FOR BAL PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	249.31 Cr	280.36 Cr	303.1 Cr	338.54 Cr
Sales	245.74 Cr	278.85 Cr	300.59 Cr	325.66 Cr
Processing Charges / Service Income	0	21,000	0	0
Net Sales	249.31 Cr	280.36 Cr	303.1 Cr	338.54 Cr
Increase/Decrease in Stock	5.13 Cr	-4.85 Cr	-17.9 Cr	-1.06 Cr
Raw Material Consumed	135.36 Cr	159.55 Cr	174.01 Cr	176.84 Cr
Opening Raw Materials	24.96 Cr	22.71 Cr	30.98 Cr	36.31 Cr
Purchases Raw Materials	123.13 Cr	159.43 Cr	167.95 Cr	154.22 Cr
Closing Raw Materials	22.71 Cr	30.98 Cr	36.31 Cr	24.92 Cr
Other Direct Purchases / Brought in cost	9.98 Cr	8.4 Cr	11.39 Cr	11.23 Cr
Power & Fuel Cost	4.7 Cr	5.37 Cr	6.87 Cr	7.57 Cr
Electricity & Power	4.7 Cr	3.35 Cr	4 Cr	4.61 Cr
Oil, Fuel & Natural gas	0	1.78 Cr	2.71 Cr	2.75 Cr
Employee Cost	39.62 Cr	44.46 Cr	51.91 Cr	56.11 Cr
Salaries, Wages & Bonus	34.89 Cr	39.33 Cr	46.13 Cr	49.95 Cr
Contributions to EPF & Pension Funds	1.59 Cr	1.48 Cr	1.74 Cr	2.17 Cr
Workmen and Staff Welfare Expenses	2.19 Cr	2.61 Cr	3 Cr	2.81 Cr
Other Manufacturing Expenses	19.21 Cr	26.49 Cr	34.02 Cr	34.03 Cr
Sub-contracted / Out sourced services	4.08 Cr	7.97 Cr	11.82 Cr	10.18 Cr
Repairs and Maintenance	3.04 Cr	4.41 Cr	5.07 Cr	5.22 Cr
Packing Material Consumed	10.08 Cr	11.79 Cr	13.83 Cr	15.96 Cr
General and Administration Expenses	4.97 Cr	6.67 Cr	9.55 Cr	11.34 Cr
Rent , Rates & Taxes	1.28 Cr	1.93 Cr	2.82 Cr	3.04 Cr
Insurance	41.19 Lk	48.47 Lk	67.61 Lk	1.4 Cr
Printing and stationery	34.36 Lk	28.92 Lk	36.83 Lk	39.24 Lk
Professional and legal fees	1.39 Cr	2.41 Cr	2.15 Cr	2.13 Cr
Traveling and conveyance	56.21 Lk	59.84 Lk	1.92 Cr	2.81 Cr
Selling and Distribution Expenses	10 Cr	15.47 Cr	15.89 Cr	18.61 Cr
Advertisement & Sales Promotion	1.41 Cr	2.22 Cr	2.9 Cr	3.21 Cr
Sales Commissions & Incentives	2.51 Cr	3.4 Cr	3.71 Cr	8.67 Cr
Freight and Forwarding	6.08 Cr	9.86 Cr	9.28 Cr	6.73 Cr
Miscellaneous Expenses	3.82 Cr	3.5 Cr	2.59 Cr	2.48 Cr
Provision for doubtful debts	21.17 Lk	15.88 Lk	18.2 Lk	19.3 Lk
Loss on disposal of fixed assets(net)	55,000	0	0	0
Loss on foreign exchange fluctuations	1.89 Cr	0	1.36 Cr	91.05 Lk
Total Expenditure	222.81 Cr	256.66 Cr	276.94 Cr	305.92 Cr
Other Income	2.69 Cr	6.49 Cr	2.15 Cr	3.35 Cr
Interest Received	1.75 Cr	1.72 Cr	1.42 Cr	1.62 Cr
Profit on sale of Fixed Assets	4.06 Lk	1.23 Cr	3.94 Lk	7.08 Lk
Provision Written Back	57.81 Lk	1.62 Cr	0	0
Foreign Exchange Gains	0	68.59 Lk	0	0
Operating Profit	29.19 Cr	30.2 Cr	28.31 Cr	35.98 Cr
Interest	12.14 Cr	10.9 Cr	12.28 Cr	15.42 Cr
Interest on Term Loan	3.26 Cr	2.77 Cr	3.7 Cr	3.12 Cr
Bank Charges etc	1.62 Cr	2.03 Cr	1.82 Cr	2.54 Cr
PBDT	17.05 Cr	19.29 Cr	16.03 Cr	20.56 Cr
Depreciation	7.26 Cr	7.24 Cr	7.48 Cr	8.45 Cr
Profit Before Taxation & Exceptional Items	9.8 Cr	12.06 Cr	8.55 Cr	12.11 Cr
Profit Before Tax	9.8 Cr	12.06 Cr	8.55 Cr	12.11 Cr
Provision for Tax	69.93 Lk	3.48 Cr	2.42 Cr	1.83 Cr
Current Income Tax	37.87 Lk	4.48 Cr	2.58 Cr	3.2 Cr
Deferred Tax	32.06 Lk	-1.94 Cr	39.21 Lk	1.08 Cr
Profit After Tax	9.1 Cr	8.58 Cr	6.13 Cr	10.27 Cr
Consolidated Net Profit	9.1 Cr	8.58 Cr	6.13 Cr	10.27 Cr
Profit Balance B/F	26.17 Cr	35.27 Cr	42.37 Cr	46.94 Cr
Appropriations	35.27 Cr	43.85 Cr	48.49 Cr	57.21 Cr
Other Appropriation	0	1.48 Cr	1.56 Cr	1.57 Cr
Equity Dividend %	10	10	10	12
Earnings Per Share	6.14	5.79	3.9	6.5
Adjusted EPS	6.14	5.79	3.9	6.5

Consolidated Standalone

CONSOLIDATED CASH FLOW FOR BAL PHARMA LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	4.1 Cr	9.18 Cr	4.75 Cr	9.05 Cr
Adjustment	21.14 Cr	18.29 Cr	21.44 Cr	22.34 Cr
Changes In working Capital	-3.35 Cr	1.69 Cr	-27.52 Cr	-4.04 Cr
Cash Flow after changes in Working Capital	21.89 Cr	29.16 Cr	-1.34 Cr	27.35 Cr
Cash Flow from Operating Activities	21.78 Cr	27.71 Cr	-1.84 Cr	22.81 Cr
Cash Flow from Investing Activities	-4.98 Cr	-9.48 Cr	-22.18 Cr	-18.89 Cr
Cash Flow from Financing Activitie	-16.63 Cr	-18.13 Cr	24.4 Cr	-1.21 Cr
Net Cash Inflow / Outflow	16.83 Lk	8.92 Lk	37.44 Lk	2.71 Cr
Opening Cash & Cash Equivalents	85.87 Lk	1.02 Cr	1.11 Cr	1.49 Cr
Effect of Foreign Exchange Fluctuations	-36,000	0	0	0
Closing Cash & Cash Equivalent	1.02 Cr	1.11 Cr	1.49 Cr	4.2 Cr

STANDALONE CASH FLOW FOR BAL PHARMA LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	9.8 Cr	12.06 Cr	8.55 Cr	12.11 Cr
Adjustment	17.44 Cr	15.12 Cr	18.55 Cr	19.66 Cr
Changes In working Capital	-16.89 Cr	5.67 Cr	-21.52 Cr	1.73 Cr
Cash Flow after changes in Working Capital	10.35 Cr	32.84 Cr	5.57 Cr	33.5 Cr
Cash Flow from Operating Activities	10.24 Cr	31.48 Cr	5.07 Cr	28.95 Cr
Cash Flow from Investing Activities	-6.66 Cr	-13.43 Cr	-22.08 Cr	-18.43 Cr
Cash Flow from Financing Activitie	-3.36 Cr	-18.13 Cr	17.43 Cr	-7.71 Cr
Net Cash Inflow / Outflow	21.81 Lk	-7.98 Lk	41.6 Lk	2.81 Cr
Opening Cash & Cash Equivalents	67.64 Lk	89.11 Lk	81.12 Lk	1.23 Cr
Effect of Foreign Exchange Fluctuations	-36,000	0	0	0
Closing Cash & Cash Equivalent	89.09 Lk	81.13 Lk	1.23 Cr	4.04 Cr

Consolidated Standalone

CONSOLIDATED BALANCE SHEET FOR BAL PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	14.82 Cr	14.82 Cr	15.69 Cr	15.8 Cr
Equity - Authorised	20 Cr	20 Cr	20 Cr	20 Cr
Equity - Issued	14.82 Cr	14.82 Cr	15.69 Cr	15.8 Cr
Equity Paid Up	14.82 Cr	14.82 Cr	15.69 Cr	15.8 Cr
Face Value	10	10	10	10
Total Reserves	37.82 Cr	42.87 Cr	48.1 Cr	53.49 Cr
Securities Premium	26.68 Cr	27.59 Cr	31.58 Cr	31.95 Cr
Capital Reserves	44.06 Lk	44.06 Lk	44.06 Lk	44.06 Lk
Profit & Loss Account Balance	9.45 Cr	13.58 Cr	14.6 Cr	19.25 Cr
General Reserves	2.45 Cr	2.45 Cr	2.45 Cr	2.45 Cr
Reserve excluding Revaluation Reserve	37.82 Cr	42.87 Cr	48.1 Cr	53.49 Cr
Shareholder's Funds	53.58 Cr	58.63 Cr	63.79 Cr	69.29 Cr
Minority Interest	-22.78 Lk	-13.44 Lk	-8.67 Lk	-3.29 Lk
Secured Loans	23.93 Cr	27.01 Cr	30.52 Cr	24.41 Cr
Term Loans - Banks	9.97 Cr	12.23 Cr	12.26 Cr	11.01 Cr
Unsecured Loans	0	0	0	11.93 Cr
Loans - Others	0	0	0	11.93 Cr
Deferred Tax Assets / Liabilities	2.63 Cr	60.44 Lk	70.25 Lk	1.55 Cr
Deferred Tax Assets	4.51 Cr	9.01 Lk	4.89 Cr	3.51 Cr
Deferred Tax Liability	7.15 Cr	69.45 Lk	5.59 Cr	5.06 Cr
Other Long Term Liabilities	3.56 Cr	4.08 Cr	1.68 Cr	1.83 Cr
Long Term Provisions	4.07 Cr	4.69 Cr	5.07 Cr	5.09 Cr
Total Non-Current Liabilities	34.19 Cr	36.4 Cr	37.97 Cr	44.81 Cr
Trade Payables	47.17 Cr	65.56 Cr	78.92 Cr	77.46 Cr
Sundry Creditors	47.17 Cr	65.56 Cr	78.92 Cr	77.46 Cr
Other Current Liabilities	23.57 Cr	24.21 Cr	31.05 Cr	26.65 Cr
Bank Overdraft / Short term credit	1.3 Cr	0	0	0
Advances received from customers	5.97 Cr	6.28 Cr	12.47 Cr	8.6 Cr
Interest Accrued But Not Due	46.48 Lk	46.79 Lk	17.7 Lk	15.8 Lk
Short Term Borrowings	80.82 Cr	70.75 Cr	92.72 Cr	95.76 Cr
Secured ST Loans repayable on Demands	75.05 Cr	64.98 Cr	86.95 Cr	89.99 Cr
Working Capital Loans- Sec	75.05 Cr	65.11 Cr	86.95 Cr	89.34 Cr
Short Term Provisions	97.87 Lk	5.12 Cr	6.64 Cr	3.17 Cr
Provision for Tax	32.26 Lk	4.39 Cr	6.01 Cr	2.22 Cr
Total Current Liabilities	152.53 Cr	165.64 Cr	209.33 Cr	203.04 Cr
Total Liabilities	240.08 Cr	260.53 Cr	311.01 Cr	317.11 Cr
Gross Block	105.1 Cr	111.14 Cr	127.1 Cr	137.52 Cr
Less: Accumulated Depreciation	36.52 Cr	43.75 Cr	50.64 Cr	60.7 Cr
Net Block	68.59 Cr	67.39 Cr	76.46 Cr	76.82 Cr
Capital Work in Progress	0	1.61 Cr	0	47.22 Lk
Quoted	0	11.08 Lk	11.08 Lk	11.08 Lk
Unquoted	0	1.5 Lk	1.5 Lk	1.5 Lk
Long Term Loans & Advances	4.86 Cr	5.01 Cr	4.61 Cr	5.23 Cr
Other Non Current Assets	2.49 Cr	1.95 Cr	1.78 Cr	45.21 Lk
Total Non-Current Assets	75.93 Cr	75.96 Cr	82.85 Cr	82.97 Cr
Currents Investments	0	0	0	6.76 Cr
Unquoted	0	1.5 Lk	1.5 Lk	1.5 Lk
Inventories	60.39 Cr	74.4 Cr	98 Cr	87.81 Cr
Raw Materials	22.72 Cr	31.1 Cr	36.35 Cr	24.95 Cr
Work-in Progress	12.04 Cr	18.44 Cr	27.48 Cr	30.92 Cr
Finished Goods	21.42 Cr	19.91 Cr	28.75 Cr	26.38 Cr
Packing Materials	4.16 Cr	4.88 Cr	5.36 Cr	5.49 Cr
Stores and Spare	3.98 Lk	5.24 Lk	6.58 Lk	7.35 Lk
Sundry Debtors	67.2 Cr	75.31 Cr	93.98 Cr	99.62 Cr
Debtors more than Six months	0	0	1.46 Cr	8.71 Cr
Debtors Others	67.95 Cr	76.23 Cr	93.98 Cr	92.57 Cr
Cash and Bank	3.85 Cr	5.39 Cr	7.61 Cr	13.29 Cr
Cash in hand	19.64 Lk	2.87 Lk	2.8 Lk	4.02 Lk
Balances at Bank	3.65 Cr	5.37 Cr	7.58 Cr	13.25 Cr
Other Current Assets	4.69 Cr	12.26 Cr	3.73 Cr	4.58 Cr
Interest accrued and or due on loans	0	6.16 Cr	0	0
Prepaid Expenses	8.02 Lk	58.55 Lk	71.95 Lk	96.9 Lk
Short Term Loans and Advances	28.02 Cr	17.21 Cr	24.83 Cr	22.08 Cr
Advances recoverable in cash or in kind	9.42 Cr	4.19 Cr	6.48 Cr	4.82 Cr
Advance income tax and TDS	1.6 Lk	9.92 Lk	14.54 Lk	11.67 Lk
Total Current Assets	164.15 Cr	184.57 Cr	228.16 Cr	234.15 Cr
Net Current Assets (Including Current Investments)	11.61 Cr	18.93 Cr	18.82 Cr	31.1 Cr
Total Assets	240.08 Cr	260.53 Cr	311.01 Cr	317.11 Cr
Contingent Liabilities	4.34 Cr	16.24 Cr	16.44 Cr	16.96 Cr
Total Debt	110.02 Cr	103.64 Cr	131 Cr	139.6 Cr
Book Value	35.52	0	40.66	43.84
Adjusted Book Value	35.52	38.92	40.66	43.84

STANDALONE BALANCE SHEET FOR BAL PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	14.82 Cr	14.82 Cr	15.69 Cr	15.8 Cr
Equity - Authorised	20 Cr	20 Cr	20 Cr	20 Cr
Equity - Issued	14.82 Cr	14.82 Cr	15.69 Cr	15.8 Cr
Equity Paid Up	14.82 Cr	14.82 Cr	15.69 Cr	15.8 Cr
Face Value	10	10	10	10
Total Reserves	63.56 Cr	70.65 Cr	78.95 Cr	89.11 Cr
Securities Premium	26.68 Cr	26.68 Cr	30.18 Cr	31.29 Cr
Capital Reserves	44.06 Lk	44.06 Lk	44.06 Lk	44.06 Lk
Profit & Loss Account Balance	35.27 Cr	42.37 Cr	46.94 Cr	55.64 Cr
General Reserves	2.45 Cr	2.45 Cr	2.45 Cr	2.45 Cr
Reserve excluding Revaluation Reserve	63.56 Cr	70.65 Cr	78.95 Cr	89.11 Cr
Shareholder's Funds	79.32 Cr	87.32 Cr	96.03 Cr	105.58 Cr
Secured Loans	23.93 Cr	27.01 Cr	30.52 Cr	23.21 Cr
Term Loans - Banks	9.97 Cr	12.47 Cr	12.26 Cr	11.01 Cr
Unsecured Loans	0	0	0	13.14 Cr
Loans - Others	0	0	0	13.14 Cr
Deferred Tax Assets / Liabilities	4.4 Cr	2.47 Cr	2.86 Cr	3.94 Cr
Deferred Tax Assets	2.27 Cr	2.91 Cr	2.72 Cr	1.1 Cr
Deferred Tax Liability	6.67 Cr	5.37 Cr	5.58 Cr	5.04 Cr
Other Long Term Liabilities	3.04 Cr	3.63 Cr	1.22 Cr	1.34 Cr
Long Term Provisions	3.97 Cr	4.6 Cr	4.91 Cr	4.93 Cr
Total Non-Current Liabilities	35.35 Cr	37.72 Cr	39.52 Cr	46.56 Cr
Trade Payables	48.56 Cr	71.93 Cr	90.77 Cr	89.84 Cr
Sundry Creditors	48.56 Cr	71.93 Cr	90.77 Cr	89.84 Cr
Other Current Liabilities	22.3 Cr	22.47 Cr	27.8 Cr	26.17 Cr
Bank Overdraft / Short term credit	1.3 Cr	0	0	0
Advances received from customers	5.97 Cr	6.28 Cr	10.25 Cr	8.53 Cr
Interest Accrued But Not Due	46.48 Lk	46.79 Lk	17.7 Lk	15.8 Lk
Short Term Borrowings	75.05 Cr	65.11 Cr	86.95 Cr	89.99 Cr
Secured ST Loans repayable on Demands	75.05 Cr	65.11 Cr	86.95 Cr	89.99 Cr
Working Capital Loans- Sec	75.05 Cr	65.11 Cr	86.95 Cr	89.34 Cr
Short Term Provisions	96.92 Lk	5.06 Cr	6.63 Cr	3.15 Cr
Provision for Tax	32.26 Lk	4.39 Cr	6.01 Cr	2.22 Cr
Total Current Liabilities	146.87 Cr	164.57 Cr	212.15 Cr	209.16 Cr
Total Liabilities	261.54 Cr	289.61 Cr	347.7 Cr	361.3 Cr
Gross Block	86.13 Cr	92.12 Cr	107.22 Cr	117.25 Cr
Less: Accumulated Depreciation	33.48 Cr	39.22 Cr	44.15 Cr	52.69 Cr
Net Block	52.65 Cr	52.9 Cr	63.07 Cr	64.56 Cr
Capital Work in Progress	0	1.16 Cr	0	47.22 Lk
Non Current Investments	8.4 Cr	8.4 Cr	8.4 Cr	9.58 Cr
Long Term Investment	8.4 Cr	8.4 Cr	8.4 Cr	9.58 Cr
Quoted	0	11.08 Lk	11.08 Lk	11.08 Lk
Unquoted	9.57 Cr	9.58 Cr	9.58 Cr	9.59 Cr
Long Term Loans & Advances	4.8 Cr	4.94 Cr	4.51 Cr	5.1 Cr
Other Non Current Assets	2.49 Cr	1.95 Cr	1.78 Cr	45.21 Lk
Total Non-Current Assets	68.34 Cr	69.35 Cr	77.75 Cr	80.16 Cr
Currents Investments	0	0	0	6.76 Cr
Unquoted	9.57 Cr	9.58 Cr	9.58 Cr	9.59 Cr
Inventories	60.12 Cr	73.97 Cr	97.69 Cr	87.49 Cr
Raw Materials	22.71 Cr	30.98 Cr	36.31 Cr	24.92 Cr
Work-in Progress	12.04 Cr	18.44 Cr	27.48 Cr	30.92 Cr
Finished Goods	21.18 Cr	19.62 Cr	28.48 Cr	26.1 Cr
Packing Materials	4.16 Cr	4.88 Cr	5.36 Cr	5.49 Cr
Stores and Spare	3.18 Lk	4.35 Lk	5.11 Lk	5.88 Lk
Sundry Debtors	69.44 Cr	77.91 Cr	94.84 Cr	103.1 Cr
Debtors more than Six months	0	11.52 Cr	16.9 Cr	12.47 Cr
Debtors Others	70.2 Cr	67.3 Cr	79.4 Cr	92.29 Cr
Cash and Bank	3.72 Cr	5.09 Cr	7.35 Cr	13.13 Cr
Cash in hand	17.34 Lk	2.32 Lk	79,000	2.08 Lk
Balances at Bank	3.54 Cr	5.07 Cr	7.34 Cr	13.11 Cr
Other Current Assets	9.49 Cr	12.23 Cr	11.06 Cr	12.98 Cr
Interest accrued and or due on loans	4.82 Cr	6.16 Cr	7.36 Cr	8.42 Cr
Prepaid Expenses	6.88 Lk	56.68 Lk	69.96 Lk	96.37 Lk
Short Term Loans and Advances	50.43 Cr	51.07 Cr	59.01 Cr	57.67 Cr
Advances recoverable in cash or in kind	10.57 Cr	5.71 Cr	6.92 Cr	6.37 Cr
Advance income tax and TDS	35,000	0	0	0
Total Current Assets	193.2 Cr	220.26 Cr	269.95 Cr	281.14 Cr
Net Current Assets (Including Current Investments)	46.33 Cr	55.69 Cr	57.8 Cr	71.98 Cr
Total Assets	261.54 Cr	289.61 Cr	347.7 Cr	361.3 Cr
Contingent Liabilities	4.34 Cr	16.24 Cr	16.44 Cr	16.96 Cr
Total Debt	104.25 Cr	98.01 Cr	125.23 Cr	133.83 Cr
Book Value	52.88	0	0	66.38
Adjusted Book Value	52.88	57.66	60.32	66.38

Consolidated Standalone

FINANCIAL RATIOS (CONSOLIDATED) FOR BAL PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	3.2	3.79	1.64	4.68
CEPS(Rs)	9.6	9.95	7.49	11.08
DPS(Rs)	1	0	1	1.2
Book NAV/Share(Rs)	35.52	38.92	40.66	43.84
Tax Rate(%)	-14.86	37.87	44.84	17.7
Margin Ratios
Core EBITDA Margin(%)	9.84	8.53	8.3	9.35
EBIT Margin(%)	6.49	7.14	5.61	7.22
Pre Tax Margin(%)	1.64	3.27	1.56	2.67
PAT Margin (%)	1.88	2.03	0.86	2.19
Cash Profit Margin (%)	5.68	5.24	3.86	5.16
Performance Ratios
ROA(%)	1.97	2.28	0.92	2.37
ROE(%)	8.97	10.34	4.31	11.19
ROCE(%)	9.72	12.33	9.56	12.13
Asset Turnover(x)	1.05	1.12	1.06	1.08
Sales/Fixed Asset(x)	2.47	2.6	2.55	2.56
Working Capital/Sales(x)	21.57	14.86	16.16	10.91
Efficiency Ratios
Fixed Capital/Sales(x)	0.4	0.38	0.39	0.39
Receivable days	85.08	92.48	101.56	104.16
Inventory Days	93.31	87.47	103.42	99.97
Payable days	72.54	132.11	165.9	162.36
Valuation Parameters
PER(x)	16.8	28.49	40.83	19.51
PCE(x)	5.6	10.84	8.94	8.23
Price/Book(x)	1.51	2.77	1.65	2.08
Yield(%)	1.86	0	1.49	1.32
EV/Net Sales(x)	0.74	0.92	0.75	0.8
EV/Core EBITDA(x)	7.21	8.86	8.72	7.83
EV/EBIT(x)	11.43	12.85	13.39	11.05
EV/CE(x)	0.77	0.99	0.73	1.3
M Cap / Sales	0.32	0.57	0.35	0.43
Growth Ratio
Net Sales Growth(%)	46.43	12.25	8.18	11.51
Core EBITDA Growth(%)	274.74	12.99	-10.09	31.95
EBIT Growth(%)	2138.49	23.56	-15.08	43.52
PAT Growth(%)	136.55	21.07	-54.09	184.26
EPS Growth(%)	137.11	18.33	-56.7	185.36
Financial Stability Ratios
Total Debt/Equity(x)	2.09	1.8	2.05	2.01
Current Ratio(x)	1.08	1.11	1.09	1.15
Quick Ratio(x)	0.69	0.67	0.62	0.72
Interest Cover(x)	1.34	1.84	1.39	1.59
Total Debt/Mcap(x)	1.38	0.65	1.25	0.97

FINANCIAL RATIOS (STANDALONE) FOR BAL PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	6.14	5.79	3.9	6.5
CEPS(Rs)	11.03	10.67	8.67	11.85
DPS(Rs)	1	1	1	1.2
Book NAV/Share(Rs)	52.88	57.66	60.32	66.38
Tax Rate(%)	7.14	28.84	28.34	15.14
Margin Ratios
Core EBITDA Margin(%)	10.63	8.45	8.63	9.64
EBIT Margin(%)	8.8	8.19	6.87	8.13
Pre Tax Margin(%)	3.93	4.3	2.82	3.58
PAT Margin (%)	3.65	3.06	2.02	3.03
Cash Profit Margin (%)	6.56	5.64	4.49	5.53
Performance Ratios
ROA(%)	3.63	3.11	1.92	2.9
ROE(%)	12.61	10.47	6.8	10.3
ROCE(%)	12.57	12.45	10.25	11.95
Asset Turnover(x)	1	1.02	0.95	0.96
Sales/Fixed Asset(x)	2.96	3.15	3.04	3.02
Working Capital/Sales(x)	5.38	5.03	5.24	4.7
Efficiency Ratios
Fixed Capital/Sales(x)	0.34	0.32	0.33	0.33
Receivable days	88.65	95.91	104.01	106.71
Inventory Days	93.46	87.29	103.36	99.83
Payable days	76.12	142.13	190.52	187.52
Valuation Parameters
PER(x)	8.76	18.63	17.14	14.04
PCE(x)	4.87	10.11	7.72	7.7
Price/Book(x)	1.02	1.87	1.11	1.37
Yield(%)	1.86	0.93	1.49	1.32
EV/Net Sales(x)	0.72	0.9	0.74	0.78
EV/Core EBITDA(x)	6.17	8.37	7.87	7.36
EV/EBIT(x)	8.21	11.01	10.7	9.62
EV/CE(x)	0.69	0.87	0.64	1.11
M Cap / Sales	0.32	0.57	0.35	0.43
Growth Ratio
Net Sales Growth(%)	46.07	12.46	8.11	11.69
Core EBITDA Growth(%)	174.27	3.43	-5.28	25.7
EBIT Growth(%)	506.37	4.65	-8.05	30.21
PAT Growth(%)	202.19	-5.69	-28.59	67.68
EPS Growth(%)	197.71	-5.69	-32.54	66.46
Financial Stability Ratios
Total Debt/Equity(x)	1.33	1.15	1.32	1.28
Current Ratio(x)	1.32	1.34	1.27	1.34
Quick Ratio(x)	0.91	0.89	0.81	0.93
Interest Cover(x)	1.81	2.11	1.7	1.79
Total Debt/Mcap(x)	1.31	0.61	1.19	0.93

SHARE HOLDING PATTERN FOR BAL PHARMA LIMITED

Date	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters %	47.79	47.79	47.43	47.43	34.61	47.43	47.09	47.09	47.09	46.74
FII %	0.30	0.20	0.18	0.00	0.17	0.14	0.13	0.13	0.13	0.13
DII %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Public %	47.71	47.80	48.21	48.23	48.23	48.25	48.64	48.64	48.64	49.01

PEER COMPARISON FOR BAL PHARMA LIMITED

No.	Name
1	AMBALAL SARABHAI ENTERPRISES LTD
2	Cipla Limited
3	Dr. Reddy's Laboratories Limited
4	Procter & Gamble Health Limited
5	J.K.PHARMACHEM LTD
6	Lupin Limited
7	Lyka Labs Limited
8	MESCO PHARMACEUTICALS LTD
9	Morepen Laboratories Limited
10	Piramal Enterprises Limited
11	Torrent Pharmaceuticals Limited
12	Abbott India Limited
13	GlaxoSmithKline Pharmaceuticals Limited
14	Sanofi India Limited
15	Pfizer Limited
16	Bliss GVS Pharma Limited
17	Alembic Limited
18	Unichem Laboratories Limited
19	AstraZeneca Pharma India Limited
20	GUJARAT THEMIS BIOSYN LTD
21	JB Chemicals & Pharmaceuticals Limited
22	TTK Healthcare Limited
23	Jagsonpal Pharmaceuticals Limited
24	Gufic Biosciences Limited
25	Sequent Scientific Limited
26	Albert David Limited
27	IOL Chemicals and Pharmaceuticals Limited
28	Wanbury Limited
29	Kopran Limited
30	Aarti Drugs Limited
31	Orchid Pharma Limited
32	Biofil Chemicals & Pharmaceuticals Limited
33	Marksans Pharma Limited
34	IPCA Laboratories Limited
35	Kilitch Drugs (India) Limited
36	Krebs Biochemicals and Industries Limited
37	Neuland Laboratories Limited
38	Ind-Swift Limited
39	Hester Biosciences Limited
40	Parenteral Drugs (India) Limited
41	Sun Pharmaceutical Industries Limited
42	Hikal Limited
43	Caplin Point Laboratories Limited
44	Aurobindo Pharma Limited
45	Natco Pharma Limited
46	Bal Pharma Limited
47	BDH INDUSTRIES LTD
48	Venus Remedies Limited
49	Jubilant Pharmova Limited
50	Themis Medicare Limited

CORPORATE ACTIONS FOR BAL PHARMA

Exchange Date	Purpose	Book Closure Dates
BSE 30-Aug-2024	Board Meeting - Inter alia, to consider and approve:- 1. Allotment of equity shares to the employees of the Company upon conversion of stock options vested on them. 2. To consider expanding its manufacturing presence to meet growing demand for API's. 3.Any other matters incidental to the business operations and ensuing AGM of the Company.	09-Sep-2024
BSE 14-Aug-2024	Book Closure - Rs.1.2000 per share(12%)Final Dividend & A.G.M.	19-Sep-2024 25-Sep-2024
BSE 14-Aug-2024	AGM - Rs.1.2000 per share(12%)Final Dividend & A.G.M.	25-Sep-2024 25-Sep-2024
BSE 26-Jul-2024	Board Meeting - Employees Stock Option Plan & A.G.M. & Quarterly Results	12-Aug-2024
BSE 26-Jul-2024	AGM - Employees Stock Option Plan & A.G.M. & Quarterly Results
BSE 28-May-2024	Dividend - Rs.1.2000 per share(12%)Final Dividend
BSE 30-Apr-2024	Board Meeting - Audited Results & Final Dividend & Inter alia, to consider and approve:- 1. Recommendation of Dividend, if any, for the financial year ended 31.03.2024. 2.Appoinment of Internal Auditors, Cost Auditors and Secretarial Auditors for f.y ended 31.03.2024.	28-May-2024
BSE 25-Jan-2024	Board Meeting - Quarterly Results	12-Feb-2024
BSE 20-Oct-2023	Board Meeting - Employees Stock Option Plan & Quarterly Results	08-Nov-2023
BSE 11-Aug-2023	Book Closure - Rs.1.0000 per share(10%)Final Dividend & A.G.M.	19-Sep-2023 25-Sep-2023
BSE 11-Aug-2023	AGM - Rs.1.0000 per share(10%)Final Dividend & A.G.M.	25-Sep-2023 25-Sep-2023
BSE 01-Aug-2023	Board Meeting - Quarterly Results & A.G.M.	11-Aug-2023
BSE 29-May-2023	Dividend - Rs.1.0000 per share(10%)Final Dividend
BSE 16-May-2023	Board Meeting - Audited Results & Final Dividend	29-May-2023
BSE 27-Jan-2023	Board Meeting - Quarterly Results	06-Feb-2023
BSE 04-Nov-2022	Board Meeting - Quarterly Results & Employees Stock Option Plan Inter alia, to consider:- 1. To allot equity shares to the eligible employees, upon exercise of ESOP's. 2. To convene Extra Ordinary General Meeting ( EGM ) for merger of Golden Drugs Pvt Ltd , a wholly owned subsidiary of the Company.	14-Nov-2022
BSE 29-Jul-2022	Board Meeting - Quarterly Results	11-Aug-2022
BSE 22-Jul-2022	Book Closure - Rs.1.0000 per share(10%)Final Dividend & A.G.M.	15-Sep-2022 19-Sep-2022
BSE 22-Jul-2022	AGM - Rs.1.0000 per share(10%)Final Dividend & A.G.M.	19-Sep-2022 19-Sep-2022
BSE 30-May-2022	Dividend - Rs.1.0000 per share(10%)Final Dividend
BSE 12-May-2022	Board Meeting - Final Dividend & Audited Results	30-May-2022
BSE 05-Apr-2022	Board Meeting - Preferential Issue of shares	13-Apr-2022
BSE 09-Mar-2022	Merger Demerger - Inter alia, has considered and approved the Scheme of Merger (the "Scheme") pursuant to Sections 230 to 232 and other applicable provisions of the Companies Act, 2013, if any, providing for the merger of its wholly owned subsidiary- Golden Drugs Private Limited (?Transferor Company") with Bal Pharma Limited ("Transferee Company"). The Scheme would be implemented subject to the requisite statutory ...	09-Mar-2022
BSE 28-Feb-2022	Board Meeting - Inter alia consider approval of scheme of amalgamation between Bal Pharma Ltd and its wholly owned subsidiary i.e Golden Drugs Private Ltd , subject to the approval of applicable statutes and shareholders of the Company.	09-Mar-2022
BSE 28-Jan-2022	Board Meeting - Quarterly Results	10-Feb-2022
BSE 22-Oct-2021	Board Meeting - Quarterly Results	11-Nov-2021

CORPORATE ANNOUNCEMENTS FOR BAL PHARMA

Exchange Date	Category File	Description
BSE 18-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding loss of share certificates as per Regulation 39(3) of SSEBI(LODR) Regulations.
BSE 15-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding issue of Duplicate share certificates as per Regulation 39(3) of SEBI(LODR) Regulations 2015.
BSE 04-Oct-2024	General Announcements FILE	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Certificate under Regulation 74(5) of SEBI(DP) Regulations 2018 for the quarter ended 30.09.2024.
BSE 01-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Disclosure of details of loss of share certificates.
BSE 27-Sep-2024	Intimation FILE	Closure of Trading Window Intimation regarding closure of Trading Window .
BSE 26-Sep-2024	Outcome FILE	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report We are submitting the Scrutinizers report on the e-voting done at the 37th Annual General Meeting of the Company held on 25.09.2024.
BSE 25-Sep-2024	Outcome FILE	Shareholder Meeting / Postal Ballot-Outcome of AGM We are submitting to the exchanges the out come of the 37th Annual General Meeting of the Company held on 25.09.2024.
BSE 11-Sep-2024	General Announcements FILE	Addendum To The Outcome Of The Board Meeting Further to our intimation to the exchanges reg the Outcome of Board meeting dated 09.09.2024 we would like to clarify that the actual cost of the project that is being undertaken at Kadechur KIADB Industrial area Yadgir Distriact Karnataka is estimated to be around Rs.40 Crores and not Rs.30 Crores as stated in our above mentioned intimation inadvertently.Request you to please take this intimation on record.
BSE 09-Sep-2024	Outcome FILE	Board Meeting Outcome for Outcome Of The Board Meeting Outcome of the Board Meeting- Announcement under Regulation 30 of SEBI(LODR) Regulations.
BSE 02-Sep-2024	Intimation FILE	Notice For The 37Th Annual General Meeting. We are submitting to the exchange Notice for the 37th Annual General Meeting of the Company scheduled to be held on 25th September 2024 at 11.30 A.M through AV means.
BSE 30-Aug-2024	Intimation FILE	Board Meeting Intimation for 1. Allotment Of Equity Shares To The Employees Of The Company Upon Conversion Of Stock Options Vested On Them.2. To Consider Expanding Its Manufacturing Presence To Meet Growing Demand For API''s. BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/09/2024 inter alia to consider and approve 1. Allotment of equity shares to the employees of the Company upon conversion of stock options vested on them.2. To consider expanding its manufacturing presence to meet growing demand for APIs.3.Any other matters incidental to the business operations and ensuing AGM of the Company.
BSE 30-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication 37th Annual General Meeting Notice & Book closure Intimation.
BSE 30-Aug-2024	General Announcements FILE	Reg. 34 (1) Annual Report. We are submitting the unabridged Annual Report of the Company for the financial year ended 31.03.2024.
BSE 19-Aug-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation as per Regulation 39(3) of SEBI(LODR) Regulations 2015 regarding issue of duplicate share certificates.
BSE 14-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication We are submitting to the exchanges copies of published results for the quarter ended 30.06.2024.
BSE 12-Aug-2024	Intimation FILE	Dividend And 37Th Annual General Meeting Of The Company. Register of Members and Share Transfer books of the company will remain closed from 19th September 2024 to 25th September 2024 ( both days inclusive ) to ascertain the entitlement of Dividend and for 37th Annual General Meeting of the Company .
BSE 12-Aug-2024	Outcome FILE	Unaudited Financial Results For The Quarter Ended 30.06.2024. Taken on record and Approved the Unaudited financial results of the Company for the quarter ended 30.06.2024.
BSE 12-Aug-2024	Outcome FILE	Board Meeting Outcome for Outcome Of The Board Meeting Inter alia 1.Taken on record and approved the Unaudited financial results of the Company for the quarter ended 30.06.2024.2. Convened 37th Annual General Meeting of the Company on 25th September 2024.3. Decided to close the Register of Members and Share transfer books of the Company from 19.09.2024 to 25.09.2024(both days inclusive ) to ascertain the entitlement of Dividend and for 37th AGM.4.Approved the re-classification of promoter share holding subject to the approval of shareholders.
BSE 26-Jul-2024	Intimation FILE	Board Meeting Intimation for Inter Alia Take On Record And Approve The Un-Audited Financial Results For The Quarter Ended 30.06.2024. BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2024 inter alia to consider and approve 1. Un-Audited financial Results for the quarter ended 30.06.2024.2.To review the requests of the promoters for reclassification.3. To convene 37th Annual General Meeting of the Company.4. To Decide on Book Closure dates.5. Other AGM related matters.6. Allotment of equity shares to the employees of the Company upon conversion of stock options.
BSE 16-Jul-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Disclosure of details of loss of share certificates as per regulation 39(3) of SEBI (LODR) Regulations 2015.
BSE 04-Jul-2024	General Announcements FILE	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 We are submitting the confirmation of compliance with Regulation 74(5) SEBI(DP) Regulations for the quarter ended 30.06.2024.
BSE 28-Jun-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Change in Directorate We would like to inform the exchanges that Dr.C.V Srinivas ( DIN# 04495304) Independent Director of the Company has completed his tenure of five years as Independent Director of the Company and he ceases to be on the Board of the Company w.e.f 28.06.2024.
BSE 25-Jun-2024	Intimation FILE	Closure of Trading Window Trading Window of the Company on designated persons and their immediate relatives will be closed from 1st July 2024 until 48 hours of declaration of the Un Audited financial results for the quarter ended 30.06.2024.
BSE 03-Jun-2024	General Announcements FILE	Disclosure under Regulation 30A of LODR Disclosure as per Regulation 31 A of SEBI (LODR) Regulations- Intimation reg receipt of applications from promoters for reclassification of their shareholding in the Company as Public holding.
BSE 30-May-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication In compliance with Regulation 47 of SEBI(LODR) Regulations we are submitting the newspaper advertisements of the abridged Audited standalone and consolidated financial results of the company for the quarter and year ended 31.03.2024 announced by the Company on 28.05.2024 and published in Financial Express ( English) and Snajayvani ( Kannada ) on 29.05.2024.
BSE 29-May-2024	Outcome FILE	Corporate Action-Board approves Dividend Board of Directors of the Company at their meeting held on 28.05.2024 has recommended payment of Dividend of Re.1.20 paise per equity share of Rs.10 each i.e 12% which is subject to the approval of the shareholders of the Company at the ensuing Annual General Meeting .
BSE 28-May-2024	Outcome FILE	Audited Financial Results_31.03.2024 Audited stand alone & Consolidated financial results for the quarter and financial year ended 31.03.2024 to gather with declaration of unmodified opinion and audit reports issued by statutory auditors.
BSE 28-May-2024	Outcome FILE	Board Meeting Outcome for Outcome Of The Board Meeting Board of Directors of the Company has met today and inter alia transacted the following business 1.Approved the audited financial results ( Stand alone & Consolidated ) for the quarter and financial year ended 31.03.2024. Copies of the approved financial results along with Declaration of Unmodified opinion and Audit reports issued by the statutory auditors are enclosed for submitting to the exchanges. 2. Recommended a Dividend of Rs.1.20 per equity share of Rs.10 each i.e 12% which is subject to the approval of shareholders at the ensuing AGM.2. Reappointed Mr.M.R Krishna Murthy Cost Accountant as Cost Auditor M/s Murugesh & Co Chartered Accountants as Internal auditors and Mr.Parameshwar Bhat PCS as Secretarial Auditors of the Company for the F.Y 2024-25.
BSE 27-May-2024	Compliance FILE	Compliances-Reg.24(A)-Annual Secretarial Compliance We are submitting the Annual Secretarial Compliance report duly certificated by the practicing Company Secretary for the financial year ended 31.03.2024.
BSE 21-May-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation reg loss of Share Certificate

INSIDER TRADING FOR BAL PHARMA

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
BSE 27-Aug-2021 27-Aug-2021	Buy Market	300,900 @ 0.00 (2.03 %)	MICRO LABS LTD
BSE 23-Nov-2021 23-Nov-2021	Buy Market	400,000 @ 0.00 (2.70 %)	MICRO LABS LTD

BULK BLOCK DEALS FOR BAL PHARMA LIMITED

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
BSE 23-Nov-2021	Buy BULK	273,704 @ 92.40	MICRO LABS LTD
BSE 23-Nov-2021	Sell BULK	273,704 @ 92.40	VIPUL KUMAT

DIVIDEND BY BAL PHARMA LIMITED

Ex Dividend Date	Dividend Type	Dividend
17-Sep-2024	DIVIDEND	1.2
18-Sep-2023	DIVIDEND	1
13-Sep-2022	DIVIDEND	1
16-Sep-2021	DIVIDEND	1

SPLIT / BONUS BY BAL PHARMA LIMITED

No Split / Bonus details found

Data feed Source : www.accordfintech.com, NSE DATA Feed & BSE Data Feed

Facebook

Twitter

To TOP

Bal Pharma Limited

Bal Pharma share price

CONSOLIDATED QUARTERLY RESULT FOR BAL PHARMA LIMITED

STANDALONE QUARTERLY RESULT FOR BAL PHARMA LIMITED

CONSOLIDATED ANNUAL RESULT FOR BAL PHARMA LIMITED

STANDALONE ANNUAL RESULT FOR BAL PHARMA LIMITED

CONSOLIDATED PROFIT / LOSS FOR BAL PHARMA LIMITED

STANDALONE PROFIT / LOSS FOR BAL PHARMA LIMITED

CONSOLIDATED CASH FLOW FOR BAL PHARMA LIMITED

STANDALONE CASH FLOW FOR BAL PHARMA LIMITED

CONSOLIDATED BALANCE SHEET FOR BAL PHARMA LIMITED

STANDALONE BALANCE SHEET FOR BAL PHARMA LIMITED

FINANCIAL RATIOS (CONSOLIDATED) FOR BAL PHARMA LIMITED

FINANCIAL RATIOS (STANDALONE) FOR BAL PHARMA LIMITED

SHARE HOLDING PATTERN FOR BAL PHARMA LIMITED

PEER COMPARISON FOR BAL PHARMA LIMITED

CORPORATE ACTIONS FOR BAL PHARMA

CORPORATE ANNOUNCEMENTS FOR BAL PHARMA

INSIDER TRADING FOR BAL PHARMA

BULK BLOCK DEALS FOR BAL PHARMA LIMITED

DIVIDEND BY BAL PHARMA LIMITED

SPLIT / BONUS BY BAL PHARMA LIMITED